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clinical and preclinical) and skills needed to perform adequately dur-
ing the following 18 month internship that is required to obtain the 
medical license. CP contents, results, and student perceptions from 
the first 3 occasions are presented.
Patients (or Materials) and Methods: The examination takes place in 
the last semester of the 5.5-year training program. The 6 stations are 
equally weighted in the total result. The students can pass the exam if 
they fail at 1 station, as long as their average score is sufficient. The 
CP station has consisted of a computer-presented patient case with 
questions, aimed at assessing prescribing skills and has also included 
preclinical aspects. Students have been allowed to use the Internet to 
search for information but not to interact with other persons. The 
cases so far have included the evaluation of possible side effects in 
an elderly patient with polypharmacy admitted after falling, drug 
prescribing to a pregnant woman with a urinary tract infection and 
migraine, and the reasoning about terminating or continuing treat-
ment with several medicines initiated by another prescriber. Students’ 
perceptions of the exam were collected through group interviews or 
questionnaires in direct connection to examination.
Results: Five percent of students failed the exam as a whole, whereas 
the failure rate at the CP station was somewhat higher; 7% to 14%. 
The failure rate was higher at the stations with more theoretical 
content such as CP, compared with stations assessing skills in com-
munication and physical examination or procedures. Within the CP 
station, preclinical questions had a higher failure rate than the more 
clinically oriented. Also, only 16% of prescription forms were filled 
out correctly. Students’ comments have included that it is essential 
that the scenarios are perceived as authentic and that it is difficult to 
go from practical stations, like a cardiac resuscitation scenario, to 
“computer patients.” A few technical problems with the computers 
were perceived as very disturbing.
Conclusion: A clinical pharmacology station can be a valuable part 
of an integrated final exam and is well suited for the assessment 
of practical prescribing performances, as well as students' abilities 
to integrate preclinical knowledge and clinical reasoning. Scenarios 
must be perceived as authentic, and access to the Internet can thus 
be a natural part of the setting.
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Introduction: In contrast to the diagnostic part of the medical record 
(MR), the therapeutic section of the MR is currently unstructured 
and does not provide guidelines on which items of the (pharmaco)
therapy are essential to note in the MR. The omission of this infor-
mation could result in prescribing errors and miscommunication 
between doctors. A previous study showed that both junior doc-
tors and clinical consultants believe it is important to note extensive 
information in the MR about the selected (pharmaco) therapy. This 
study investigated the effect of a structured MR on the completeness 
of therapeutic information in the MR and the extent to which doctors 
felt informed about the treatment (as an indicator of communication 
between doctors).
Patients (or Materials) and Methods: Fifteen junior doctors work-
ing in the outpatient department of internal medicine in 7 Dutch 
teaching hospitals recorded therapeutic information for 2 weeks in 
regular, unstructured MRs. Subsequently after receiving a short train-
ing, they had to record their therapeutic information for 4 weeks in 
a structured MR. The structure contained 21 therapeutic items that 
should be recorded. The recording of these therapeutic items was then 
evaluated in 223 unstructured MRs and 197 structured MRs. After 
this evaluation, independent clinical consultants in internal medicine 
were asked to score, on a 5-point scale, the extent to which they felt 
informed about the treatment.
Results: Seven of the 21 (33%) therapeutic items were recorded in sig-
nificantly (P < 0.05) greater detail in the structured MRs. Clinical con-
sultants did not feel significantly more informed about treatment (score 
3.9 with unstructured MRs and 4.0 with structured MRs; P = 0.25).
Conclusion: Structuring the therapeutic part of the MR improves 
the documentation of therapeutic information, but doctors did not 
feel more informed about the treatment.
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Introduction: The Scottish Medicines Consortium (SMC) provides 
advice about the clinical and cost-effectiveness of newly licensed 
medicines to the National Health Service (NHS) in Scotland, and 
since 2005, SMC has also provided early intelligence on medicines 
still in development through publication of “Forward Look” reports. 
Forward Look predictions are helpful in supporting resource plan-
ning by NHS Boards, but there are challenges in accurately estimating 
the uptake of a medicine that is still in development. This study exam-
ined how actual medicine use compared with predictions provided 
in Forward Look Reports and SMC advice.
Patients (or Materials) and Methods: Twenty-eight medicines were 
selected in line with specified criteria. Data on the predicted uptake 
of these medicines at year 1 were extracted from Forward Look 
reports and SMC advice and compared with actual medicine use 
data from national primary and secondary care datasets. The data 
were summarized in medicine profiles and reviewed by clinicians to 
identify factors that may have impacted on the accuracy of predic-
tions provided in Forward Look reports and SMC advice.
Results: Of 28 medicines selected for evaluation, the actual acquisi-
tion cost per patient per annum was consistent with Forward Look 
predictions for 11 medicines, higher for 14 medicines, and lower for 
3 medicines. Of 22 medicines in the sample that were accepted for use 
or restricted use by SMC, the actual uptake at year 1 was consistent 
with Forward Look predictions for 4 medicines and with predictions 
in SMC advice for 3 medicines. Forward Look was more likely to 
overestimate the uptake than the SMC advice. Review of the medicine 
profiles identified 7 factors that may explain the variation between 
predicted and actual medicines uptake
- SMC “not recommended” advice
-  Accuracy of the predicted acquisition cost and number of patients 
(uptake being the product of these)
- Availability of alternative treatment
- Comparative costs and service implications
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- Adverse effects
-  Prescribing within clinical trials and availability of unlicensed medi-
cines
- License extension
Conclusion: This investigation found variation between actual 
uptake of new medicines and the predictions provided in Forward 
Look reports and SMC advice. The 7 factors identified assist in 
explaining the variations observed, are useful in understanding the 
challenges in making accurate predictions, and provide some areas 
in which action could be taken to further develop and potentially 
improve predictions in Forward Look reports and SMC advice.
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Introduction: Drug manufacturers developed “evergreening strate-
gies” to compete with generic medication after patent termination. 
These include marketing of slightly modified follow-on drugs. We 
identified 8 follow-on drugs available in the canton of Geneva during 
the study period: 3 drugs for which an isomer had been marketed 
(levocetirizine as follow-on drug of cetirizine; escitalopram/citalo-
pram; esomeprazole/omeprazole); 1 active metabolite (desloratidine 
– loratidine); 2 combination formulations of the originally patented 
drug (alendronic acid alone – alendronic acid combined with colecal-
ciferol; simvastatin alone – simvastatin with ezetimib); 1 slow-release 
formulation (zolpidem extended release); and 1 structural analogue 
(pregabaline – gabapentine). We aimed to estimate the financial 
impact of these drugs on overall health care costs.
Patients (or Materials) and Methods: The impact of evergreening 
strategies on health care spending was analyzed in the community 
database that includes > 73% of the total of insured patients. Costs 
were analyzed under 3 scenarios, assuming a replacement with the 
corresponding generic when available of: (1) all brand drug prescrip-
tions; (2) all follow-on; and (3) both follow-on and brand prescrip-
tions. The “extra-cost” was assessed by the difference between the 
total cost based on the observed data and the total cost estimated in 
the 3 scenarios.
Results: Based on our scenario 1 (no brand) and 2 (no follow-on) of 
“extra-costs,” the health care system could have saved over the entire 
study period € 15.9 (95% CI, 15.5–16.2) million and € 14.4 (95% CI, 
14.1–14.7) million if brand or follow-on drug prescriptions, respec-
tively, had replaced. This amounted to € 30.3 (95% CI, 29.8–30.8) 
million over the entire study period if brand and follow-on drug pre-
scriptions were replaced at their corresponding community generic 
selling price equivalents when available (scenario 3).
Conclusion: Evergreening strategies have been successful in maintain-
ing market share in Geneva, offsetting competition by generics and 
cost-containment policies. Therefore, health care providers and policy 
makers should be aware of the impact of evergreening strategies.
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Introduction: Intravenously administered Busulfan (Bu) in children 
undergoing hematopoietic stem cell transplantation (HSCT) exhibits 
therapeutic window phenomenon requiring therapeutic drug moni-
toring. The dosage of Bu is adjusted based on the first dose phar-
macokinetic parameters. Existing methods for the analysis of Bu 
require long turnaround times with relatively large amounts of blood 
collection for plasma separation.
Objective: To evaluate the utility of dried blood sampling (DBS) 
and dried plasma sampling (DPS) using only 5 μ L of whole blood or 
plasma for therapeutic monitoring of Bu levels.
Patients (or Materials) and Methods: Venous blood samples were 
collected from 2 children after the infusion of Bu at doses1, 2, 3, 5, 
and 9 (n = 34). Then, 5 μ L each of whole blood and plasma were 
spotted onto Whatman 903 DBS cards and dried at room tempera-
ture for 30 minutes. The entire spots were cut and then analyzed by 
a validated LC-MS/MS method. Bu was also measured by established 
gas chromatography coupled to mass spectrometry (GC-MS) method 
using plasma (n = 13) to compare both the methods.
Results: A good correlation was observed between the levels meas-
ured by DBS and DPS (r2 = 0.95; slope = 0.84). The Bu levels meas-
ured by DPS (r2 = 0.92; slope = 0.95) and DBS (r2 = 0.91; slope = 
0. 80) were correlated with those measured by GC-MS method. The 
levels estimated by DBS were less than those obtained by DPS and 
GC-MS methods. The hematocrit (Hct) values of 2 children were in 
the range of 25.6% to 30.3%, indicating the direct influence of Hct 
on the measured Bu levels measured by DBS sampling. Therefore, 
these 2 sampling methods can be used interchangeably with due con-
sideration of the Hct value when whole blood sample is used. The 
plasma levels can be obtained from DBS levels using the formula 
“Plasma levels (analyte) = DBS levels analyte/ (1 – hematocrit).” The 
plasma levels of Bu estimated using this formula were higher than 
